Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Kaira, Kyoichi ^a,f   Sunose, Yutaka ^a   Ohshima, Yasuhiro ^b   Ishioka, Noriko S ^b   Arakawa, Kazuhisa ^c   Ogawa, Tetsushi ^c   Sunaga, Noriaki ^a   Shimizu, Kimihiro ^a   Tominaga, Hideyuki ^a   Oriuchi, Noboru ^a,d   Itoh, Hideaki ^c   Nagamori, Shushi ^e   Kanai, Yoshikatsu ^e   Yamaguchi, Aiko ^a   Segawa, Atsuki ^a   Ide, Munenori ^a   Mori, Masatomo ^a   Oyama, Tetsunari ^a   Takeyoshi, Izumi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN ATOMIC ENERGY AGENCY   (Japan)

^c MAEBASHI RED CROSS HOSPITAL   (Japan)

^d Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Amino acid transporter; BCH; Biliary tract cancer; LAT1; Prognostic factor

Indexed keywords

2 AMINOBICYCLO(2,2,1)HEPTANE 2 CARBOXYLIC ACID; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; L TYPE AMINO ACID TRANSPORTER 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT ADENOCARCINOMA; BILIARY TRACT SURGERY; CANCER INHIBITION; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD98; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885440579     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-482     Document Type: Article

References (39)

1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol 2002, 37:806-813. 10.1016/S0168-8278(02)00297-0, 12445422.
2. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996, 22:463-475.
3. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg 2008, 32:2675-2680. 10.1007/s00268-008-9778-3, 18843437.
4. Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, Kato K, Matsumoto J, Kawasaki R. Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci 2010, 17:455-462. 10.1007/s00534-009-0208-1, 19820891.
5. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, Yamasaki S, Takayama T, Makuuchi M. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005, 37:396-402.
6. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. ABC-02 trial investigators: cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281. 10.1056/NEJMoa0908721, 20375404.
7. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990, 70:43-77.
8. McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994, 299:321-334. 1138275, 8172590.
9. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998, 273:23629-23632. 10.1074/jbc.273.37.23629, 9726963.
10. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001, 1514:291-302. 10.1016/S0005-2736(01)00384-4, 11557028.
11. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005, 90:233-238. 10.1002/jso.20257, 15906366.
12. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008, 98:742-748. 10.1038/sj.bjc.6604235, 2259171, 18253116.
13. Nakanishi K, Ogata S, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Kawai T. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 2007, 451:681-690. 10.1007/s00428-007-0457-9, 17622555.
14. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006, 119:484-492. 10.1002/ijc.21866, 16496379.
15. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I. L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 2009, 59:7-18. 10.1111/j.1440-1827.2008.02319.x, 19121087.
16. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int 2011, 61:281-289. 10.1111/j.1440-1827.2011.02650.x, 21501294.
17. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012, 103:382-389. 10.1111/j.1349-7006.2011.02151.x, 22077314.
18. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 2011, 3:468-478. 3204889, 22046488.
19. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res 2011, 31:4075-4082.
20. Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, Kim do K. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 2008, 31:1096-1100. 10.1248/bpb.31.1096, 18520037.
21. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M, Kanai Y. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 2010, 30:4819-4828.
22. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors 2009, Oxford, UK: Wiley-Blackwell, Sobin LH, Gospodarowicz MK, Wittekind C, 7.
23. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol 2009, 16:3473-3581. 10.1245/s10434-009-0685-0, 19777189.
24. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010, 28:3746-3753. 10.1200/JCO.2009.27.4662, 20625125.
25. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 1989, 25:503-510. 10.1007/BF02623562, 2544546.
26. Homma S, Nagamori S, Fujise K, Yamazaki K, Hasumura S, Sujino H, Matsuura T, Shimizu K, Kameda H, Takaki K. Human bile duct carcinoma cell line producing abundant mucin in vitro. Gastroenterol Jpn 1987, 22:474-479.
27. Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl) 1988, 188:367-375. 10.1007/BF01851205, 2852388.
28. Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na + -independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999, 274:19745-19751. 10.1074/jbc.274.28.19745, 10391916.
29. Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, Jutabha P, Li Y, Ahmed N, Sakamoto S, Anzai N, Nagamori S, Endou H. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 2003, 273:43838-43845.
30. Bodoy S, Martín L, Zorzano A, Palacín M, Estévez R, Bertran J. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem 2005, 280:12002-12011. 10.1074/jbc.M408638200, 15659399.
31. Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E, Tachampa K, Anzai N, Iribe Y, Endou H. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 2002, 1565:112-121. 10.1016/S0005-2736(02)00516-3, 12225859.
32. Morimoto E, Kanai Y, Kim do K, Chairoungdua A, Choi HW, Wempe MF, Anzai N, Endou H. Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters. J Pharmacol Sci 2008, 108:505-516. 10.1254/jphs.08232FP, 19075510.
33. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T, Takeyoshi I. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012, 107:632-638. 10.1038/bjc.2012.310, 3419959, 22805328.
34. Yanagisawa N, Ichinoe M, Mikami T, Nakada N, Hana K, Koizumi W, Endou H, Okayasu I. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas. J Clin Pathol 2012, 65:1019-1023. 10.1136/jclinpath-2012-200826, 22813728.
35. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Iijima H, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008, 204:553-561. 10.1016/j.prp.2008.02.003, 18440724.
36. Liu XM, Reyna SV, Ensenat D, Peyton KJ, Wang H, Schafer AI, Durante W. Platelet-derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: role in cell growth. FASEB J 2004, 18:768-770.
37. Kim CS, Moon IS, Park JH, Shin WC, Chun HS, Lee SY, Kook JK, Kim HJ, Park JC, Endou H, Kanai Y, Lee BK, Kim do K. Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells. Biol Pharm Bull 2010, 33:1117-1121. 10.1248/bpb.33.1117, 20606299.
38. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP. Prognostic molecular markers in cholangiocarcinoma: a systemic review. Eur J Cancer 2009, 45:33-47. 10.1016/j.ejca.2008.08.024, 18938071.
39. Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2012, Feb 09. [Epub ahead of print].